Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Cellular Immunotherapy Market Between 2025 and 2034?

The scale of the cellular immunotherapy market has been expanding swiftly in the past years. It is projected to escalate from $5.72 billion in 2024 to $6.61 billion in 2025, representing a compound annual growth rate (CAGR) of 15.7%. The growth witnessed in the earlier phase is attributed to progress in cancer treatment techniques, clinical triumphs, regulatory green lights and the increasing cases of targeted diseases.

Expectations are high for a swift expansion in the cellular immunotherapy market in the coming years. Predictions suggest an increase to $11.27 billion by 2029, translating to a compound annual growth rate (CAGR) of 14.2%. The anticipated growth during the forecast period can be associated with developments in solid tumors, enhanced manufacturing processes, improvements in healthcare infrastructure, and an increase in research funding. The forecast period is likely to witness substantial trends such as investment in research and development, data from clinical trials, and the emergence of combination therapies.

Which Drivers Are Expected to Have the Greatest Impact on the Cellular Immunotherapy Market’s Growth?

The cellular immunotherapy market is anticipated to grow due to the rising scope of research and promising results from clinical trials in this area. Many companies are turning their attention to create new forms of cellular immunotherapies to combat various diseases. For instance, as per a report by the Cancer Research Institute in June 2022, a US-based organization committed to crafting immunotherapy for the prevention, treatment, and eventual elimination of all forms of cancer, there were 2,756 active cell therapy drugs in the global immuno-oncology pipeline as of April 2022. This marked a 36% rise from the overall tally of 2021 which stood at 2,031, although this did represent a modest slump from the 43% growth recorded the previous year. It is believed that the quickened pace of cellular immunotherapy developments in clinical and preclinical stages in 2020 when compared with 2019, will help broaden the scope of cellular immunotherapy, hence promoting the expansion and large-scale revenue generation in the cellular immunotherapy market.

Get Your Free Sample of the Global Cellular Immunotherapy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Are the Key Firms That Are Driving Transformation in the Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

What Current Trends in the Cellular Immunotherapy Market Should Industry Players Pay Attention To?

Firms within the cellular immunotherapy sphere are concentrating on the creation of new and superior cancer treatments through off-the-shelf allogeneic therapies. These therapies, unlike autologous therapies, are derived from donor cells rather than the patient’s own cells. They offer benefits such as cost efficiency, large scale production, speed, and quality control owing to their non-customized nature. For example, Novartis AG, a Swiss pharmaceutical company proficient in drug discovery, development, production, and commercialization, revealed in May 2022 that the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah (tisagenlecleucel) for treating adults with relapsed or refractory (r/r) follicular lymphoma (FL) who have undergone two or more systemic therapies. Furthermore, Acepodia, an American company that specializes in state-of-the-art cell immuno-technology, is set to commence a phase 1 clinical trial in August 2020 to assess ACE1702, an allogeneic, off-the-shelf NK cell therapy created for solid tumor treatment.

Get Instant Access to the Global Cellular Immunotherapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Growth-Oriented Segments of the Cellular Immunotherapy Market Are Leading the Industry’s Development?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

What Regions Are Driving Expansion in the Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Parameters Define the Cellular Immunotherapy Market’s Scope?

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body’s immune system to combat cancer.

Browse Through More Similar Reports By The Business Research Company:

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Colorectal Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: